Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has scheduled its Q2 2025 financial results release for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET the same day to discuss results and provide business updates.
Management will conduct a Q&A session for analysts, and a webcast replay will be available on the investor website approximately two hours after the call concludes. Participants are encouraged to join 15 minutes before the start time.
Biodesix (Nasdaq: BDSX), azienda specializzata in soluzioni diagnostiche, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025 dopo la chiusura dei mercati. La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno per discutere i risultati e fornire aggiornamenti aziendali.
Il management condurrà una sessione di domande e risposte per gli analisti e una registrazione della webcast sarà disponibile sul sito degli investitori circa due ore dopo la conclusione della chiamata. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell’inizio.
Biodesix (Nasdaq: BDSX), una empresa de soluciones diagnósticas, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025 después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 PM ET del mismo día para discutir los resultados y proporcionar actualizaciones comerciales.
La dirección llevará a cabo una sesión de preguntas y respuestas para analistas, y una repetición de la transmisión estará disponible en el sitio web de inversores aproximadamente dos horas después de que finalice la llamada. Se recomienda a los participantes conectarse 15 minutos antes del inicio.
Biodesix (나스닥: BDSX)는 진단 솔루션 회사로서 2025년 2분기 재무 결과를 2025년 8월 7일 장 마감 후에 발표할 예정입니다. 회사는 같은 날 오후 4시 30분(동부 시간)에 컨퍼런스 콜과 웹캐스트를 개최하여 결과를 논의하고 사업 현황을 업데이트할 예정입니다.
경영진은 애널리스트들을 위한 질의응답 시간을 진행하며, 콜 종료 약 두 시간 후에 투자자 웹사이트에서 웹캐스트 재방송을 제공할 예정입니다. 참가자들은 시작 15분 전에 접속할 것을 권장합니다.
Biodesix (Nasdaq : BDSX), une entreprise spécialisée dans les solutions diagnostiques, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025 après la clôture des marchés. La société organisera une conférence téléphonique et une diffusion en webcast à 16h30 ET le même jour afin de discuter des résultats et de fournir des mises à jour commerciales.
La direction animera une session de questions-réponses pour les analystes, et un replay du webcast sera disponible sur le site des investisseurs environ deux heures après la fin de l’appel. Les participants sont invités à se connecter 15 minutes avant le début.
Biodesix (Nasdaq: BDSX), ein Unternehmen für diagnostische Lösungen, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025 nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und Geschäftsinformationen bereitzustellen.
Das Management wird eine Fragerunde für Analysten durchführen, und eine Wiederholung des Webcasts wird etwa zwei Stunden nach Ende des Anrufs auf der Investorenseite verfügbar sein. Teilnehmer werden gebeten, sich 15 Minuten vor Beginn einzuwählen.
- None.
- None.
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024 or subsequent quarterly reports on Form 10-Q during 2024, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ
When will Biodesix (BDSX) release Q2 2025 earnings?
What time is the Biodesix Q2 2025 earnings call?
How can I access the Biodesix Q2 2025 earnings call?
Will there be a replay of the Biodesix Q2 2025 earnings call?
